NCM · Biotechnology

REVB (REVB) Stock

$1.06 +0.00% NCM: REVB Healthcare

Valuation

MetricValue
Price$1.06
Market Cap$4.14M
P/E Ratio-0.05
P/B Ratio0.47
P/S Ratio0.00
EPS (TTM)$-23.95
52-Week High$12.88
52-Week Low$0.88
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-100.00%
ROA-75.00%
ROCE-100.00%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.06
Current Ratio5.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-12.0M$-11.0M$-9.0M$-8.0M$-9.0M
Net Profit$-12.0M$-11.0M$0$-15.0M$-9.0M
EPS$-20400.00$-9643.37$-8.41$-87.68$-23.95
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$2.0M$6.0M$12.0M$7.0M$12.0M
Total Liabilities$2.0M$4.0M$6.0M$2.0M$3.0M
Cash$1.0M$5.0M$12.0M$6.0M$11.0M
Borrowings$0$0$0$0$1.0M

Latest News

Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ACCESS Newswire · Jul 21, 2026 Revelation Biosciences Adopts Stockholder Rights Plan MT Newswires · Jul 10, 2026 Revelation Biosciences Announces Adoption of Stockholder Rights Plan ACCESS Newswire · Jul 10, 2026 Revelation Biosciences Expands Acute Kidney Injury Advisory Board ACCESS Newswire · Jun 1, 2026 Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders ACCESS Newswire · May 11, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-11.0M$-11.0M$-7.0M$-18.0M$-8.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$12.0M$0$0$0
Net Cash Flow$-3.0M$4.0M$7.0M$-5.0M$4.0M
Free Cash Flow$-11.0M$-11.0M$-7.0M$-18.0M$-8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-205.67%
Quick Ratio10.02
Interest Coverage—
Return 1Y-90.51%
Return 3Y-99.98%
Return 5Y-100.00%

Ownership

Insiders Held4.79%
Institutions Held12.79%
Institutions Float Held13.43%
Institutional HolderSharesReport Date
Armistice Capital, LLC323,2412026-03-31
Sabby Management, LLC99,4322026-03-31
Geode Capital Management, LLC43,1952026-03-31
Vanguard Fiduciary Trust Co13,1272026-03-31
Xtx Topco Ltd11,3852026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATXIAvenue Therapeutics, Inc. $0.26 -32.94% -0.49 $856691 0.00%
AZTR $0.14 +0.80% -0.09 $1.49M 0.00%
GTBP $0.29 -4.65% -0.07 $3.12M 0.00%
INDP $1.39 -3.82% -0.06 $2.43M 0.00%
NKGNNKGen Biotech, Inc. $0.06 +0.00% -0.04 $7.84M 0.00%

About REVB

REVB is led by CEO James Rolke, employs 8 people, headquartered in US, publicly traded since 2020.

REVB stock trades at $1.06 with a market capitalization of $4.14M. The stock is valued at a price-to-earnings (P/E) ratio of -0.05, price-to-book of 0.47, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.88 and $12.88, and currently trades 91.8% below its 52-week high.

On profitability, REVB generates a return on equity (ROE) of -100.00%, return on capital employed of -100.00%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides